United States Patent 8,137,992: Claim Scope, Exclusivity, Litigation Risk, and Dopamine-Agonist Patent Landscape

U.S. Patent No. 8,137,992 covers a patient-selection and treatment protocol for cardiovascular disease using dopamine agonists, particularly bromocriptine. Its core limitation is a biomarker-based selection rule involving norepinephrine, dopamine, serotonin, metabolites, fasting triglycerides, and blood pressure. The patent does not broadly claim bromocriptine treatment for all cardiovascular patients. It requires both a defined identification process and administration of dopamine-agonist therapy.

The strongest infringement risk would arise where a product sponsor, clinical investigator, or provider deliberately uses the claimed biomarker thresholds to select cardiovascular patients for bromocriptine treatment. A conventional bromocriptine prescription without the claimed screening protocol presents a materially narrower risk.

What does U.S. Patent 8,137,992 claim?

U.S. Patent 8,137,992 is directed to methods of identifying and treating patients with metabolic or cardiovascular disease using dopamine agonist therapy. The claims supplied identify three principal elements:

Claim	Claimed subject matter	Principal limitation
1	Patient identification	Analysis of plasma or urine biomarkers and identification of abnormal catecholamine, serotonin, triglyceride, or blood-pressure levels
2	Treatment method	Identification under claim 1 followed by a pharmaceutically effective dopamine-agonist regimen
3	Bromocriptine treatment	Claim 2 where the dopamine agonist is bromocriptine

The independent diagnostic-selection claim requires:

Analysis of a plasma or urine sample.
Measurement of one or more specified analytes.
A defined abnormality, including:
- One or more norepinephrine metabolites above approximately 30% of normal;
- A norepinephrine or metabolite-to-dopamine or dopamine-metabolite relationship above the stated threshold;
- Elevated norepinephrine and serotonin or serotonin metabolites;
- Elevated norepinephrine alone;
- Dopamine or dopamine metabolites below approximately 30% of normal;
- Fasting triglycerides above 150 mg/dL;
- Blood pressure above 135/85 mm Hg.
A patient suffering from cardiovascular disease.

Claim 2 adds administration of dopamine agonist therapy. Claim 3 narrows the therapy to bromocriptine.

How broad is the scope of claim 1?

Claim 1 is broad in analyte selection but narrow in procedural structure. It does not require every listed biomarker. The wording uses alternative combinations, meaning that infringement may be established through any one qualifying branch if all other claim elements are met.

The practical scope can be represented as follows:

Claim pathway	Required abnormality
A	Elevated norepinephrine metabolites
B	Elevated norepinephrine or metabolites relative to dopamine or dopamine metabolites
C	Elevated norepinephrine and serotonin
D	Elevated norepinephrine or metabolites and serotonin
E	Elevated norepinephrine and serotonin metabolites
F	Elevated norepinephrine or metabolites and serotonin metabolites
G	Elevated norepinephrine
H	Reduced dopamine or dopamine metabolites
I	Fasting triglycerides above 150 mg/dL
J	Blood pressure above 135/85 mm Hg

The claim therefore reaches beyond specialized catecholamine testing. A patient-selection protocol based only on fasting triglycerides or blood pressure may fall within the stated identification criteria, provided the patient has cardiovascular disease and the protocol otherwise satisfies the claim.

The principal narrowing feature is the requirement to analyze a plasma or urine sample for specified biochemical markers. Blood pressure alone does not satisfy the sample-analysis requirement unless the claim is interpreted as permitting the blood-pressure branch to complete the threshold condition after the required sample analysis.

What are the key limitations and claim-construction issues?

What does “normal level” mean?

The phrase “normal level” is central to claim 1. The claim does not define whether normal means:

A population reference interval;
A healthy control group;
A laboratory-specific reference range;
The patient’s prior baseline;
A matched age, sex, or disease subgroup.

That ambiguity creates claim-construction and enablement issues. A court would likely examine the specification, examples, laboratory methods, and technical meaning of “normal” at the relevant filing date.

How should “about 30%” be interpreted?

The term “about” introduces numerical flexibility. The enforceable range may depend on intrinsic evidence, experimental examples, prosecution history, and accepted analytical variability. A defendant could argue that a result slightly above or below the 30% threshold is outside the claim, while the patent holder could argue that normal laboratory and biological variation supports a broader range.

Does claim 1 require all listed tests?

The claim language appears to establish alternatives rather than cumulative testing. The use of “or” and the enumerated pathways indicate that a protocol need not test every analyte. The specification and prosecution record would control whether the claim requires testing of at least one biomarker from the list or a more particular combination.

What is the effect of the cardiovascular-disease limitation?

The cardiovascular-disease requirement materially narrows the claims. A protocol directed to obesity, type 2 diabetes, metabolic syndrome, or hypertension without cardiovascular disease may fall outside the literal scope of the supplied claims, although claim interpretation may depend on the specification’s definition of cardiovascular disease.

What does claim 2 add to the patent scope?

Claim 2 is a treatment-method claim. It requires:

Identification of a patient under claim 1; and
Administration of an effective dopamine-agonist regimen.

This structure is important. The claim does not cover every administration of bromocriptine to a cardiovascular patient. It requires the claimed identification step before or as part of the treatment method.

Potential infringement theories would focus on:

Clinical protocols that order the claimed laboratory tests;
Treatment algorithms that use the specified thresholds;
Electronic medical-record decision tools that identify qualifying patients;
Clinical trials enrolling patients under the biomarker criteria;
Product labeling or promotional materials instructing clinicians to use the selection criteria.

A physician who administers bromocriptine without using the claimed screening criteria would present a weaker literal-infringement case. Induced-infringement exposure could arise if a sponsor knowingly encourages performance of the identification step and subsequent administration.

What does claim 3 protect for bromocriptine?

Claim 3 narrows claim 2 to bromocriptine. It is the commercially most relevant claim because bromocriptine is the principal dopamine agonist associated with the Cycloset product and the metabolic-cardiovascular treatment strategy described in the patent family.

Claim 3 does not appear to require:

A particular bromocriptine salt;
A specific immediate-release or extended-release tablet;
A fixed dose;
A particular administration time;
A particular number of daily doses;
A specific brand.

Those limitations may appear in the specification or other family claims, but they are not present in the supplied claim text. A bromocriptine product could therefore implicate claim 3 if it is administered as part of the claimed patient-identification and cardiovascular-treatment protocol.

What patents protect bromocriptine and Cycloset?

The relevant landscape includes several distinct patent categories:

Patent category	Protection focus	Relevance to U.S. Patent 8,137,992
Patient-selection patents	Biomarker or clinical-threshold selection	Directly relevant
Method-of-treatment patents	Bromocriptine or dopamine agonist use in metabolic disease	Overlapping therapeutic territory
Formulation patents	Release profile, tablet composition, dosing schedule	Potentially separate from the supplied claims
Manufacturing patents	Bromocriptine synthesis, salt formation, purification, solid forms	Product and supply-chain barriers
Regulatory exclusivity	FDA approval-based protection	Separate from patent rights
Trademark and labeling rights	Cycloset branding and approved-use communications	Commercial but not patent exclusivity

The patent should not be treated as a composition-of-matter patent. Its value is method-based. A competitor may avoid it through a different patient-selection protocol, a different therapeutic class, a different disease population, or treatment without the claimed biomarker workflow.

What is the Orange Book status of U.S. Patent 8,137,992?

Orange Book listing depends on whether the patent was submitted for an approved drug product and whether it claims the approved drug, formulation, or method of use. FDA listing does not automatically follow from issuance of a patent.

For bromocriptine products, the relevant regulatory product is Cycloset, an FDA-approved bromocriptine mesylate product for glycemic control in adults with type 2 diabetes. The supplied claims are directed to cardiovascular disease and dopamine-agonist patient selection. That creates a potential mismatch with the approved indication and may affect Orange Book listing eligibility.

The following distinctions are material:

Issue	Effect
Patent claims an approved method of use	May support Orange Book listing with a use code
Patent claims an unapproved cardiovascular use	Listing may be contested or unavailable
Patent claims a formulation or dosage form	More conventional Orange Book listing basis
Patent is not listed	Generic applicants may not face a Paragraph IV certification to this patent
Patent is listed	A Paragraph IV challenge may trigger statutory litigation and a potential 30-month stay

The FDA Orange Book and approved labeling should be checked against the patent’s actual listing status rather than assuming that every Cycloset-related patent is listed.[1][2]

When does U.S. Patent 8,137,992 lose exclusivity?

The patent’s term cannot be calculated from the issue date alone. U.S. utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.[3]

The relevant dates are:

Event	Date or rule
Patent issuance	March 20, 2012
Nominal statutory term	20 years from the applicable earliest nonprovisional filing date
Patent-term adjustment	May extend the term for USPTO examination delays
Terminal disclaimer	May shorten the term if tied to an earlier-expiring patent
Patent-term extension	Potentially available for regulatory review, but not presumed
Post-expiration status	Patent rights end, subject to surviving litigation and other family rights

The issuance date does not establish the expiration date. A definitive expiration analysis requires the patent’s continuity data, earliest effective filing date, terminal-disclaimer record, and Patent Center term-adjustment data.[3][4]

Are there Paragraph IV challenges involving this patent?

A Paragraph IV challenge is relevant only if the patent is listed in the Orange Book for the reference drug and the ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.

For U.S. Patent 8,137,992, the commercial risk depends on four facts:

Whether the patent is listed for bromocriptine or Cycloset;
Whether the listed use corresponds to an FDA-approved indication;
Whether an ANDA applicant seeks approval for a product whose labeling induces the claimed use;
Whether the patent remains unexpired when the ANDA is otherwise approvable.

A generic applicant may attempt a section viii statement to carve out a patented method of use rather than issue a Paragraph IV certification. That strategy depends on whether the proposed labeling can omit the patented use without creating an induced-infringement theory.[5]

How strong is the patent estate?

The estate is strongest against a protocol that expressly combines:

Cardiovascular disease;
The specified catecholamine or serotonin testing;
The stated abnormality thresholds;
Dopamine-agonist therapy;
Bromocriptine administration.

It is weaker against ordinary bromocriptine prescribing, generic dopamine-agonist therapy, or treatment of type 2 diabetes without the claimed cardiovascular patient-selection process.

Risk factor	Assessment
Claim breadth	Moderate; multiple alternative biomarkers broaden selection coverage
Product coverage	Limited; claims are method-based
Diagnostic vulnerability	Meaningful, because the claims rely on biomarker correlations and thresholds
Treatment-claim strength	Stronger than a pure diagnostic claim because claim 2 requires administration
Design-around potential	Significant
Formulation protection	Not shown by the supplied claims
Manufacturing protection	Not shown by the supplied claims
Regulatory leverage	Depends on Orange Book listing and approved-use alignment
Biosimilar relevance	Low; bromocriptine is a small molecule, not a biologic

What patent litigation risks affect bromocriptine competitors?

Potential litigation would likely involve:

Induced infringement

A sponsor could face allegations if its labeling, training materials, clinical-support tools, or marketing instruct clinicians to perform the claimed selection process and administer bromocriptine.

Direct infringement

Direct infringement may attach to a party that performs the patient-selection and treatment steps, such as a clinical-trial sponsor, treatment network, or integrated healthcare provider.

Divided infringement

Because claim 2 requires identification and treatment, disputes may arise over whether different actors perform separate steps. Federal Circuit precedent requires a sufficiently attributable relationship among actors for divided method infringement.[6]

Subject-matter eligibility

Biomarker-based claims may face challenges under the framework of Mayo Collaborative Services v. Prometheus Laboratories and Association for Molecular Pathology v. Myriad Genetics. A treatment claim that includes administration may have stronger eligibility arguments than a claim limited to detecting a natural correlation, but eligibility depends on the claim as a whole.[7][8]

Indefiniteness and enablement

The terms “normal level,” “about 30%,” “pharmaceutically effective regimen,” and “suffering from cardiovascular disease” may be contested under 35 U.S.C. §§ 112(b) and 112(a). The result would depend on the specification, examples, prosecution history, and skilled-person understanding.[9]

What generic launch scenarios exist?

Scenario 1: Product launches without the patented use

A generic applicant may pursue a label limited to an unpatented indication or may omit the cardiovascular patient-selection language. This reduces, but does not eliminate, induced-infringement risk.

Scenario 2: Paragraph IV challenge

If the patent is Orange Book-listed, the applicant may file a Paragraph IV certification. The patent holder could bring an infringement action within 45 days, potentially creating a 30-month FDA approval stay.[5]

Scenario 3: Post-expiration launch

The generic may wait for patent expiration while relying on ordinary ANDA approval. This avoids patent litigation but may delay entry beyond the earliest lawful launch date.

Scenario 4: Non-infringing clinical protocol

A competitor may avoid the claimed thresholds, use a different disease population, administer a non-dopamine therapy, or avoid the claimed sample-analysis workflow. The commercial practicality of these approaches depends on medical evidence and labeling requirements.

How does this patent compare with formulation and manufacturing patents?

U.S. Patent 8,137,992 is more vulnerable to clinical-protocol design-around than a formulation or composition patent. A formulation patent may block a particular release profile or dosage form even where the active ingredient is unpatented. A manufacturing patent may create supply-chain exposure without appearing in the product label.

Protection type	Main competitive effect
Selection method	Controls patient identification and treatment workflow
Treatment method	Controls clinical use
Formulation	Controls product architecture and release characteristics
Manufacturing	Controls production route or supply
Composition of matter	Broadest product-level protection
Regulatory exclusivity	Delays approval independently of patent validity

The supplied claims do not establish protection over bromocriptine itself, bromocriptine mesylate as a chemical entity, a specific tablet formulation, or a manufacturing process.

Key Takeaways

U.S. Patent 8,137,992 is a method patent centered on cardiovascular patient selection for dopamine-agonist therapy.
Claim 1 uses alternative biomarker and clinical thresholds, including norepinephrine, dopamine, serotonin, triglycerides, and blood pressure.
Claim 2 requires both the claimed identification process and administration of dopamine-agonist therapy.
Claim 3 specifically targets bromocriptine treatment.
The patent does not, based on the supplied claims, broadly cover bromocriptine composition, formulation, manufacturing, or every cardiovascular use.
The principal legal vulnerabilities concern “normal level,” “about 30%,” the meaning of cardiovascular disease, diagnostic-correlation doctrine, enablement, and divided performance of the method steps.
Orange Book and Paragraph IV exposure depend on actual listing status and whether the patented use corresponds to an FDA-approved bromocriptine indication.
Biosimilar analysis is not material because bromocriptine is a small-molecule drug. The relevant pathway is the ANDA and Hatch-Waxman framework.
Generic launch risk is highest where labeling or clinical-support materials instruct users to apply the claimed thresholds before administering bromocriptine.

FAQs

Does U.S. Patent 8,137,992 cover all bromocriptine prescriptions?

No. The supplied claims require a specified patient-identification process tied to cardiovascular disease. Ordinary bromocriptine prescribing without that process presents a narrower infringement case.

Can a generic avoid the patent by removing cardiovascular language from its label?

Potentially, if the resulting label does not encourage the patented method and the product is not otherwise promoted for the claimed use. The analysis depends on the final labeling, promotional conduct, and Orange Book status.

Does the patent cover dopamine agonists other than bromocriptine?

Claim 2 covers dopamine-agonist therapy generally as supplied. Claim 3 narrows the method to bromocriptine. Other dopamine agonists may fall within claim 2 if all claim limitations are met.

Are fasting triglycerides alone enough to satisfy the patient-selection threshold?

The supplied text identifies fasting triglycerides above 150 mg/dL as one qualifying condition. The complete infringement analysis must also account for the sample-analysis and cardiovascular-disease requirements.

Is this patent relevant to biosimilar competition?

No. Bromocriptine is a small molecule. Competition would generally proceed through an ANDA rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2009). Cycloset (bromocriptine mesylate) prescribing information. FDA.
United States Code. (2023). 35 U.S.C. §§ 154, 156. Office of the Law Revision Counsel.
U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 8,137,992. USPTO.
United States Code. (2023). 21 U.S.C. § 355(j). Office of the Law Revision Counsel.
Akamai Technologies, Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015).
Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
United States Code. (2023). 35 U.S.C. § 112. Office of the Law Revision Counsel.

Details for Patent: 8,137,992

Summary for Patent: 8,137,992